NCT02967120

Brief Summary

The purpose of this study is to verify the function of p16 hydroxymethylation diagnostic reagents in early diagnosis of oral cancer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
265

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
2.9 years until next milestone

First Submitted

Initial submission to the registry

November 16, 2016

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 17, 2016

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2018

Completed
Last Updated

September 25, 2017

Status Verified

September 1, 2017

Enrollment Period

4 years

First QC Date

November 16, 2016

Last Update Submit

September 20, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Cancer rate in patients with oral epithelial dysplasia containing or NOT containing p16 hydroxymethylation

    Among these cases, oral specimens from 24 patients were p16-hydroxymethylation, 54 patients were p16-methylation and 187 patients were p16-unmethylation. The cancer rate in the p16-hydroxymethylation patients during the followup period will be compared with that in the other two groups.

    from 3 months to 60 months

Secondary Outcomes (1)

  • Disease free survival of patients with oral epithelial dysplasia containing or Not containing p16 hydroxymethylation

    from 3 months and 36 months

Study Arms (1)

p16 hydroxymethylation status

patients with p16 hydroxymethylation

Other: no intervention

Interventions

p16 hydroxymethylation status

Eligibility Criteria

Age25 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

336 patients with mild or moderate oral epithelial dysplasia were selected. 145 of them are collected from Peking University of Stomatology and 165 were from Capital Medical University School of Stomatology and other 26 were from Fourth Military Medical University School of Stomatology.All of the patients with OED had been diagnosed pathologically by at least two senior pathologists using the criteria from '2005 WHO Classification System' and The oral tissue pathology diagnostic criteria (oral histopathology Edition Sixth).All cases involved primary lesions without any LASER, radiation therapy or chemotherapy.

You may qualify if:

  • Histopathological diagnosis of oral lesions meet the epithelial diagnostic criteria for mild to moderate grade OED;
  • No local area stimulate by residual root and crown, sharp cusp, poor restoration and biting cheek or lips;
  • Without the treatment history by laser , radiation or chemical;
  • Be able to Sign the informed consent;

You may not qualify if:

  • Histopathological diagnosis of oral lesions do not meet the epithelium of mild to moderate dysplasia diagnostic criteria; histological diagnosis of severe grade OED or malignant disease;
  • Pregnancy or breast-feeding women;
  • Serious heart, lung, liver , kidney and other systemic diseases local area stimulate by residual root and crown, sharp cusp, poor restoration and biting cheek or lips;
  • OED treatment history by LASER, radiotherapy, or chemotherapy;
  • Tumor and psychiatric patients;
  • Patients are unable to cooperate;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University Cancer Hosptial and Institute

Beijing, Beijing Municipality, 100142, China

RECRUITING

Related Publications (3)

  • Liu H, Liu XW, Dong G, Zhou J, Liu Y, Gao Y, Liu XY, Gu L, Sun Z, Deng D. P16 Methylation as an Early Predictor for Cancer Development From Oral Epithelial Dysplasia: A Double-blind Multicentre Prospective Study. EBioMedicine. 2015 Mar 23;2(5):432-7. doi: 10.1016/j.ebiom.2015.03.015. eCollection 2015 May.

    PMID: 26137587BACKGROUND
  • Cao J, Zhou J, Gao Y, Gu L, Meng H, Liu H, Deng D. Methylation of p16 CpG island associated with malignant progression of oral epithelial dysplasia: a prospective cohort study. Clin Cancer Res. 2009 Aug 15;15(16):5178-83. doi: 10.1158/1078-0432.CCR-09-0580. Epub 2009 Aug 11.

    PMID: 19671846BACKGROUND
  • Liu H, Liu Z, Liu XW, Xu S, Wang L, Liu Y, Zhou J, Gu L, Gao Y, Liu XY, Shi H, Sun Z, Deng D. A similar effect of P16 hydroxymethylation and true-methylation on the prediction of malignant transformation of oral epithelial dysplasia: observation from a prospective study. BMC Cancer. 2018 Sep 24;18(1):918. doi: 10.1186/s12885-018-4787-6.

Biospecimen

Retention: SAMPLES WITH DNA

Oral mucosal biopsy tissues were formalin fixed , paraffin embedded , sliced;or frozen tissues;

Study Officials

  • Dajun Deng, MD

    Peking University Cancer Hosptial and Institute

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

November 16, 2016

First Posted

November 17, 2016

Study Start

January 1, 2014

Primary Completion

January 1, 2018

Study Completion

January 1, 2018

Last Updated

September 25, 2017

Record last verified: 2017-09

Data Sharing

IPD Sharing
Will share

The number of the participants of different groups and the followup information will be shared with other researchers after the end of the study.

Locations